胶质母细胞瘤（GBM）是最常见和最具破坏性的原发性恶性脑肿瘤。我们总结了放射治疗、免疫治疗和靶向治疗方法在治疗新诊断和复发性胶质母细胞瘤方面的最新进展。我们还介绍了正在进行的临床试验。最近的临床试验探索了多种治疗 GBM 的新策略，包括使用肿瘤病毒、嵌合抗原受体 (CAR) T 细胞疗法、疫苗、放射疗法以及提高药物在血液中渗透性的新型药物输送技术脑屏障。改善脑肿瘤药物输送的方法有可能扩大现有疗法的治疗选择，否则这些疗法的脑肿瘤外显率较差。免疫疗法对于新诊断和复发的胶质母细胞瘤引起了浓厚的兴趣。 SurVaxM 和 DCVax-L 疫苗分别在 II 期和 III 期试验中显示出初步前景。 CAR T 细胞疗法试验尚处于早期阶段，但对新诊断的胶质母细胞瘤和复发性胶质母细胞瘤都有希望。尽管改善 GBM 患者预后的进展有限，但利用联合疗法、聚焦超声改善药物输送和新型免疫疗法的多种新策略正在进行中。版权所有 © 2024 作者。由 Wolters Kluwer Health, Inc. 出版

Glioblastoma (GBM) is the most common and devastating primary malignant brain tumor. We summarize recent advances in radiotherapy, immunotherapy, and targeted therapy approaches for the treatment of newly diagnosed and recurrent glioblastoma. We also introduce ongoing clinical trials.Recent clinical trials have explored multiple novel strategies to treat GBM including the use of oncoviruses, chimeric antigen receptor (CAR) T cell therapy, vaccines, radiotherapy, and novel drug delivery techniques to improves drug penetrance across the blood brain barrier. Approaches to improve drug delivery to brain tumors have the potential to expand treatment options of existing therapies that otherwise have poor brain tumor penetrance. Immunotherapy has been of keen interest in both newly diagnosed and recurrent glioblastoma. Vaccines SurVaxM and DCVax-L have shown initial promise in phase II and III trials, respectively. CAR T cell therapy trials are in their early phases but hold promise in both newly diagnosed and recurrent glioblastoma.Although progress to improve outcomes for GBM patients has been modest, multiple novel strategies utilizing combination therapies, focused ultrasound to improve drug delivery, and novel immunotherapies are underway.Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.